Multiple sclerosis is a chronic autoimmune disease involving the destruction of myelin in the white matter of the brain by auto reactive mediating cells mainly T lymphocytes. The disease is caused by multifactorial factors and mediated by both genetics and the environmental factors including sunlight, vitamin D, geographical location, smoking and infections. It primarily affects younger individuals, occurring more in female than male and it is the most common autoimmune condition affecting the younger population. The disease usually presents first with characteristic symptoms, but not eligible for the diagnostic criteria in a form called clinical isolated syndrome. The most common form of the disease is the relapsing remitting form, characterized by a cycle of active disease state with symptoms and symptom free state, which after some years progresses to a secondary progressive state with decreasing symptom free periods and increasing disability. The least common form is the primary progressive form characterized by insidious worsening of the symptoms with no symptom free state. It usually occurs in older individuals and is associated with a worse prognosis. Diagnosis depends mainly on the clinical history and exclusion of other diseases, in addition to imaging tests, evoked potentials and laboratory CSF examinations. It is made according to the McDonald criteria characterized by the time and space dissemination theory, with symptoms appearing during different time periods and on different images or laboratory examinations. Management of the disease is by treating the relapses with acute exacerbation treatment, disease modifying drugs to prevent the progression and symptomatic treatment for the symptoms that arise during the disease course. For treatment of acute relapses, glucocorticoids are the mainstay of treatment, given over a few days. Alternatively, e.g. in case of contraindications or non-tolerance, adrenocorticotropin hormone or plasmapheresis can be used. A variety of disease modifying drugs are available to choose from, to slow the progression of the disease, and the choice depends on the clinical course of the disease, the efficacy, and the side effects of the drug in question. Interferons and glatiramer acetate were usually the mainstay of treatment, but with increasing development nowadays, there have been newer drugs developed that are more effective including ocrelizumab, natalizumab, dimethyl fumarate, siponimod and alemtuzumab. Symptom relieving drugs are also given to 30 manage the various complaints such as pain, bladder dysfunction, gait, fatigue, spasticity that occur during the disease. The prognosis of the disease is determined mostly by the disease course, with primary progressive having a worse outlook than relapsing remitting. As a whole, disease prognosis has become better in recent years and it is no longer as fatal as it once was, as with prompt diagnosis and adequate treatment, the outlook is much better.